Clinical development of the GluN2B-selective NMDA receptor inhibitor NP10679 for the treatment of neurologic deficit after subarachnoid hemorrhage
The Journal of Pharmacology and Experimental Therapeutics · 2025-01 · 392 (1) · 100046
DOI: 10.1124/jpet.124.002334 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Pharmacology and Experimental Therapeutics, 2025-01. Verfasst von Haichen Wang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Duke University, Durham, North Carolina. Hauptthemen laut MEDLINE: Subarachnoid Hemorrhage, Receptors, N-Methyl-D-Aspartate, Neuroprotective Agents, Drug Development. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 45 Literaturangaben. Gefördert von: National Institute of Neurological Disorders and Stroke.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Duke University, Durham, North Carolina.
- Department of Pharmacology and Chemical Biology, Emory University School of Medicine, Atlanta, Georgia; Center for Neurodegenerative Disease, Emory University School of Medicine, Atlanta, Georgia.
- Department of Pharmacology and Chemical Biology, Emory University School of Medicine, Atlanta, Georgia.
- Department of Pharmacology and Chemical Biology, Emory University School of Medicine, Atlanta, Georgia; NeurOp Inc, Atlanta, Georgia.
- Department of Neurology, Duke University, Durham, North Carolina; Department of Neurosurgery, Affiliated Hospital of Hebei University, Baoding, China.
- Department of Neurology, Duke University, Durham, North Carolina; Department of Pathology, Affiliated Hospital of Hebei University, Baoding, China.
Förderung
- National Institute of Neurological Disorders and Stroke
Zitieren
APA
Wang, H., Dingledine, R. J., Myers, S. J., Traynelis, S. F., Fang, C., Tan, Y., Koszalka, G. W., & Laskowitz, D. T. (2025). Clinical development of the GluN2B-selective NMDA receptor inhibitor NP10679 for the treatment of neurologic deficit after subarachnoid hemorrhage. The Journal of Pharmacology and Experimental Therapeutics, 392(1), 100046. https://doi.org/10.1124/jpet.124.002334
Vancouver
Wang H, Dingledine RJ, Myers SJ, Traynelis SF, Fang C, Tan Y, et al. Clinical development of the GluN2B-selective NMDA receptor inhibitor NP10679 for the treatment of neurologic deficit after subarachnoid hemorrhage. The Journal of Pharmacology and Experimental Therapeutics. 2025;392(1):100046. doi:10.1124/jpet.124.002334
BibTeX
@article{Wang2025,
author = {Wang, Haichen and Dingledine, Raymond J and Myers, Scott J and Traynelis, Stephen F and Fang, Chuan and Tan, Yanli and Koszalka, George W and Laskowitz, Daniel T},
title = {Clinical development of the GluN2B-selective NMDA receptor inhibitor NP10679 for the treatment of neurologic deficit after subarachnoid hemorrhage},
journal = {The Journal of Pharmacology and Experimental Therapeutics},
year = {2025},
volume = {392},
number = {1},
pages = {100046},
doi = {10.1124/jpet.124.002334}
}
EUVIMED